Market Cap
ø95.8b
Last Updated
2020/04/07 20:55 UTC
Data Sources
Company Financials +
Executive Summary
Genmab A/S, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Genmab's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GMAB has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
6.6%
GMAB
7.1%
DK Biotechs
1.9%
DK Market
1 Year Return
26.5%
GMAB
26.9%
DK Biotechs
6.0%
DK Market
Return vs Industry: GMAB matched the Danish Biotechs industry which returned 25.6% over the past year.
Return vs Market: GMAB exceeded the Danish Market which returned 5.2% over the past year.
Shareholder returns
| GMAB | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.6% | 7.1% | 1.9% |
| 30 Day | -4.5% | -8.2% | -4.3% |
| 90 Day | 0.1% | -1.2% | -4.4% |
| 1 Year | 26.5%26.5% | 27.8%26.9% | 8.2%6.0% |
| 3 Year | 15.6%15.6% | 13.2%11.2% | 36.1%24.7% |
| 5 Year | 181.1%181.1% | 36.6%32.1% | 30.3%13.8% |
Price Volatility Vs. Market
How volatile is Genmab's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Should You Rely On Genmab's (CPH:GMAB) Earnings Growth?3 weeks ago | Simply Wall St
Do Institutions Own Shares In Genmab A/S (CPH:GMAB)?1 month ago | Simply Wall St
Is Genmab's (CPH:GMAB) Share Price Gain Of 246% Well Earned?Valuation
Is Genmab undervalued compared to its fair value and its price relative to the market?
19.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GMAB (DKK1468.5) is trading below our estimate of fair value (DKK1820.88)
Significantly Below Fair Value: GMAB is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: GMAB is good value based on its PE Ratio (42.7x) compared to the Biotechs industry average (43.3x).
PE vs Market: GMAB is poor value based on its PE Ratio (42.7x) compared to the Danish market (12.8x).
Price to Earnings Growth Ratio
PEG Ratio: GMAB is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: GMAB is overvalued based on its PB Ratio (6.8x) compared to the DK Biotechs industry average (6.8x).
Next Steps
Future Growth
How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
25.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMAB's forecast earnings growth (25% per year) is above the savings rate (-0.3%).
Earnings vs Market: GMAB's earnings (25% per year) are forecast to grow faster than the Danish market (12.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GMAB's revenue (19.8% per year) is forecast to grow faster than the Danish market (6% per year).
High Growth Revenue: GMAB's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (16.1%).
Next Steps
Past Performance
How has Genmab performed over the past 5 years?
26.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMAB has a high level of non-cash earnings.
Growing Profit Margin: GMAB's current net profit margins (40.4%) are lower than last year (48.7%).
Past Earnings Growth Analysis
Earnings Trend: GMAB's earnings have grown significantly by 26.3% per year over the past 5 years.
Accelerating Growth: GMAB's earnings growth over the past year (47.1%) exceeds its 5-year average (26.3% per year).
Earnings vs Industry: GMAB earnings growth over the past year (47.1%) exceeded the Biotechs industry 14.9%.
Return on Equity
High ROE: GMAB's Return on Equity (15.4%) is considered low.
Next Steps
Financial Health
How is Genmab's financial position?
Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK14.0B) exceed its short term liabilities (DKK938.0M).
Long Term Liabilities: GMAB's short term assets (DKK14.0B) exceed its long term liabilities (DKK158.0M).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB had no debt 5 years ago.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Genmab's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
Jan G. van de Winkel (58yo)
9.83s
Tenure
ø35,200,000
Compensation
Dr. Jan G. J. van de Winkel, Ph.D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board. He is a Co-Founder of Genmab A/S ...
CEO Compensation Analysis
Compensation vs Market: Jan G.'s total compensation ($USD5.13M) is above average for companies of similar size in the Danish market ($USD3.18M).
Compensation vs Earnings: Jan G.'s compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.83yrs | ø35.20m | 1.03% DKK981.7m | |
| Associate Director of Legal & Non-Independent Director | 4.25yrs | ø800.00k | 0.00031% DKK296.9k | |
| Executive VP & Chief Development Officer | 3.17yrs | ø17.00m | no data | |
| Director of Protein Production & Chemistry and Non-Independent Director | 1.08yrs | ø300.00k | no data | |
| VP, Corporate Controller & Non-Independent Director | 4.25yrs | ø800.00k | no data | |
| Executive VP & CFO | 0.083yr | no data | no data | |
| Executive VP & COO | 0.083yr | no data | no data | |
| Senior Director of Finance & Accounting | no data | no data | no data | |
| Head and Corporate VP of Communications & Investor Relations | 1.08yrs | no data | no data | |
| Senior Vice President of IPR & Legal | 10.25yrs | no data | no data |
2.1yrs
Average Tenure
45yo
Average Age
Experienced Management: GMAB's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Associate Director of Legal & Non-Independent Director | 4.25yrs | ø800.00k | 0.00031% DKK296.9k | |
| Director of Protein Production & Chemistry and Non-Independent Director | 1.08yrs | ø300.00k | no data | |
| VP, Corporate Controller & Non-Independent Director | 4.25yrs | ø800.00k | no data | |
| Non-Independent Director | 16.42yrs | ø1.40m | 0.013% DKK12.8m | |
| Independent Chairman of the Board | 0.083yr | ø2.20m | 0.0034% DKK3.2m | |
| Independent Director | 3.08yrs | ø1.50m | 0.0016% DKK1.5m | |
| Independent Deputy Chairman | 0.083yr | ø1.10m | 0.0049% DKK4.7m | |
| Independent Director | 0.083yr | no data | no data | |
| Independent Director | 5.25yrs | ø1.10m | 0.0051% DKK4.9m |
3.1yrs
Average Tenure
58yo
Average Age
Experienced Board: GMAB's board of directors are considered experienced (3.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Top Shareholders
Company Information
Genmab A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Genmab A/S
- Ticker: GMAB
- Exchange: CPSE
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: ø95.762b
- Shares outstanding: 65.21m
- Website: https://www.genmab.com
Number of Employees
Location
- Genmab A/S
- Kalvebod Brygge 43
- Copenhagen
- Capital Region of Denmark
- 1560
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GNMS.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Oct 2000 |
| GMAB | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Ordinary Shares | DK | DKK | Oct 2000 |
| GE9 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Oct 2000 |
| 0MGB | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | DKK | Oct 2000 |
| GMAB | NasdaqGS (Nasdaq Global Select) | SPONSORED ADS | US | USD | May 2013 | |
| GE91 | BST (Boerse-Stuttgart) | SPONSORED ADS | DE | EUR | May 2013 |
Biography
Genmab A/S, a biotechnology company, creates and develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM) indications; and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL) indications. Its products under development include Ofatumumab to treat multiple sclerosis; Tisotumab vedotin for treating cervical and ovarian cancers, and solid tumors; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company’s products under development also comprise Teprotumumab for the treatment of thyroid eye disease; Camidanlumab tesirine (ADCT-301) to treat Hodgkin lymphoma and solid tumors; HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat acute myeloid leukemia (AML); JNJ-64007957 and JNJ-64407564 for MM; JNJ-63898081 to treat solid tumors; JNJ-67571244 to treat AML or myelodysplastic syndrome; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked antibodies, bispecific antibodies, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers. It also has a research collaboration and license agreement with Immatics Biotechnologies GmbH to discover and develop next-generation bispecific immunotherapies for treating multiple cancer indications; and CureVac AG for the research and development of differentiated mRNA-based antibody products. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/07 20:55 |
| End of Day Share Price | 2020/04/07 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.